Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sean Ryan

Vascular Surgery Lewes, DE Medical Doctor

NPI 1891991402 CMS profile 872658

701 Savannah Rd Ste B, Lewes, DE 19958

Open in the dashboard

General payments

$46,755

313 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sean Ryan of Lewes, DE is reported in the CMS Open Payments database as having received $46,755 across 313 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,081 21
2024 General $11,447 38
2023 General $5,007 46
2022 General $1,979 57
2021 General $3,370 39
2020 General $3,221 36
2019 General $11,650 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Ryan
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Sean Ryan were reported at $10,081. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Sean Ryan Vascular Surgery median Middle half National median
2019 $11,650 $796 $226–$2,363 $163
2020 $3,221 $348 $118–$1,110 $114
2021 $3,370 $471 $158–$1,421 $132
2022 $1,979 $725 $222–$2,183 $149
2023 $5,007 $836 $257–$2,440 $160
2024 $11,447 $909 $252–$2,619 $164
2025 $10,081 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $27,765 11 payments
  2. Medtronic Vascular, Inc. $5,250 43 payments
  3. Cardiovascular Systems Inc. $4,151 30 payments
  4. Silk Road Medical, Inc. $2,114 37 payments
  5. W. L. Gore & Associates, Inc. $1,782 67 payments
  6. Cook Medical LLC $1,376 28 payments
  7. Boston Scientific Corporation $1,127 22 payments
  8. Medtronic, Inc. $799 17 payments
  9. Penumbra, Inc. $567 6 payments
  10. Janssen Pharmaceuticals, Inc $299 13 payments
  11. Other $1,524 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $21,944 3 payments
  2. Food and Beverage $12,530 294 payments
  3. Travel and Lodging $6,681 13 payments
  4. Education $5,600 3 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $13,333 2 payments
  2. Auryon Laser System 100-120 Vac Cv $8,611 1 payment
  3. IN.PACT Admiral $4,160 22 payments
  4. EVLT $4,000 2 payments
  5. Peripheral Orbital Atherectomy System $3,801 25 payments
  6. ENROUTE Transcarotid Stent $1,918 33 payments
  7. ENROUTE Transcarotid Neuroprotection System $1,918 33 payments
  8. VenaCure 1470 Pro $1,600 1 payment
  9. Endurant $774 13 payments
  10. C3 Delivery System $712 34 payments
  11. Other $10,653 239 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

175

Median for Vascular Surgery: 122

Drug cost

$29,535

Median for Vascular Surgery: $14,135

Branded share of claims

78.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 35 $27,569
Clopidogrel Clopidogrel Bisulfate Brand 103 $1,475
Cilostazol Generic 26 $417
Oxycodone Hcl Generic 11 $74

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$371,781

Of which drugs: $283

Medicare patients

1,372

Average age 76

Services billed

5,031

653 women, 719 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Arthritis 55%
Diabetes 37%
Chronic kidney disease 33%
Atrial fibrillation 28%
COPD 27%
Heart failure 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 23 2,450 $253

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record